Leukemia Research
Volume 26, Issue 7 , Pages 621-629 , July 2002

Potential mechanisms of resistance to cytarabine in AML patients

  • Carlos M. Galmarini

      Affiliations

    • Unité INSERM 453, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller, 8, avenue Rockefeller, 69373 Lyon Cedex 08, France
    • Corresponding Author InformationCorresponding author. Fax: +33-4-78-77-70-88
    • ,
  • Xavier Thomas

      Affiliations

    • Service d’Hématologie, Hôpital Edouard Herriot, Lyon, France
    • ,
  • Fabien Calvo

      Affiliations

    • Laboratoire de Pharmacologie (AP-HP et EP9932 INSERM CIC 9504), Hôpital Saint Louis, Paris, France
    • ,
  • Philippe Rousselot

      Affiliations

    • Service d’Hématologie, Hôpital Saint Louis, Paris, France
    • ,
  • Assia El Jafaari

      Affiliations

    • Centre de Transfusion, Hôpital Edouard Herriot, Lyon, France
    • ,
  • Emeline Cros

      Affiliations

    • Unité INSERM 453, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller, 8, avenue Rockefeller, 69373 Lyon Cedex 08, France
    • ,
  • Charles Dumontet

      Affiliations

    • Unité INSERM 453, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller, 8, avenue Rockefeller, 69373 Lyon Cedex 08, France

Received 10 July 2001 ,Accepted 3 November 2001.

References 

  1. Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer. 1999;79:831–837
  2. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SP, Deeley RG. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res. 1995;55:102–110
  3. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475–1479
  4. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, et al.  Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87:1997–2004
  5. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996;87:2464–2469
  6. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, et al.  P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol. 1999;104:328–335
  7. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 1980;255:8900–8997
  8. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–890
  9. Major PP, Egan EM, Herrick DJ, Kufe DW. Effect of ara-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol. 1982;31:2937–2940
  10. Plagemann PG, Marz R, Wohlhueter RM. Transport and metabolism of deoxycytidine and 1-β-d- arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation and regulation of triphosphate synthesis. Cancer Res. 1978;38:978–989
  11. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest. 1985;75:632–642
  12. Mackey JR, Baldwin SA, Young JD, Cass CE. The role of nucleoside transport in anticancer drug resistance. Drug Resistance Updates. 1998;1:310–324
  13. Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacol. 1997;36:1167–1179
  14. Coleman CN, Stoller RG, Drake JC, Chabner BA. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood. 1975;46:791–803
  15. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol. 1987;14:159–166
  16. Laliberte J, Momparler RL. Human cytidine deaminase: purification of enzyme, cloning and expression of its complementary DNA. Cancer Res. 1994;54:5401–5407
  17. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106:78–85
  18. Martincic D, Kravtsov V, Whitlock JA, Dumontet C. Sensitivity of HEL and K562 cell lines to topotecan correlates with the level of topoisomerase I expression activity. Proc Am Assoc Cancer Res. 1999;40:A719
  19. Goz B, Bastow KF. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-l-aspartate-resistance frequency and its enhancement by 1-β-d-arabinofuranosyl cytosine and 5-fluoro-2′-deoxyuridine. Mutat Res. 1997;384:89–106
  20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Int Med. 1985;103:620–625
  21. Pieters R, Veerman AJ. The role of 5′-nucleotidase in therapy-resistance of childhood leukemia. Med. Hypotheses. 1988;27:77–80
  22. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, van der Does-van den Berg A, et al.  Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer. 1992;51:213–217
  23. Veerman AJ, Hogeman PH, van Zantwijk CH, Bezemer PD. Prognostic value of 5′-nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. Leuk Res. 1985;9:1227–1229
  24. Arner ES, Spasokoukotskaja T, Juliusson G, Liliemark J, Eriksson S. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. Br J Haematol. 1994;87:715–718
  25. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995;67:155–186
  26. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81:597–601
  27. Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, El Jafaari A, et al.  Expression of high km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood. 2001;98:1922–1926
  28. Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today. 1999;5:216–224
  29. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood. 1997;90:346–353
  30. Gati WP, Paterson AR, Belch AR, Chlumecky V, Larratt LM, Mant MJ, et al.  Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (ara-C). Leuk Lymphoma. 1998;32:45–54
  31. Jahns-Streubel G, Reuter C, Auf der Landwehr U, Unterhalt M, Schleyer E, Wormann B, et al.  Activity of thymidine kinase and of polymerase α as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood. 1997;90:1968–1976
  32. Tattersall MH, Ganeshaguru K, Hoffbrand AV. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol. 1974;27:39–46
  33. Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol. 1971;233:109–110
  34. Colly LP, Peters WG, Richel D, Arentsen-Honders MW, Starrenburg CW, Willemze R. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Semin Oncol. 1987;14:257–261
  35. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol. 1998;103:1096–1103
  36. Schroder JK, Kirch C, Flasshove M, Kalweit H, Seidelmann M, Hilger R, et al.  Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia. 1996;10:1919–1924
  37. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, et al.  Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood. 1994;83:517–530
  38. Lohri A, van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J, et al.  Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase II α) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur J Haematol. 1997;59:206–215

PII: S0145-2126(01)00184-9

Leukemia Research
Volume 26, Issue 7 , Pages 621-629 , July 2002

Article Tools

* Image Usage & Resolution